Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates

Pochetti G, Gavuzzo E, Campestre C, Agamennone M, Tortorella P, Consalvi V, Gallina C, Hiller O, Tschesche H, Tucker PA, Mazza F (2006)
JOURNAL OF MEDICINAL CHEMISTRY 49(3): 923-931.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ; ; ; ; ;
Abstract
Potent and selective inhibitors of matrix metalloproteinases (MMPs), a family of zinc proteases that can degrade all the components of the extracellular matrix, could be useful for treatment of diseases such as cancer and arthritis. The most potent MMP inhibitors are based on hydroxamate as zinc-binding group (ZBG). alpha-Arylsulfonylamino phosphonates incorporate a particularly favorable combination of phosphonate as ZBG and arylsulfonylamino backbone so that their affinity exceptionally attains the nanomolar strength frequently observed for hydroxamate analogues. The detailed mode of binding of [1-(4'-methoxybiphenyl-4-sulfonylamino)-2-methylpropyl]phosphonate has been clarified by the crystal structures of the complexes that the R- and S-enantiomers respectively form with MMP-8. The reasons for the preferential MMP-8 inhibition by the R-phosphonate are underlined and the differences in the mode of binding of analogous alpha-arylsulfonylamino hydroxamates and carboxylates are discussed.
Publishing Year
ISSN
PUB-ID

Cite this

Pochetti G, Gavuzzo E, Campestre C, et al. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. JOURNAL OF MEDICINAL CHEMISTRY. 2006;49(3):923-931.
Pochetti, G., Gavuzzo, E., Campestre, C., Agamennone, M., Tortorella, P., Consalvi, V., Gallina, C., et al. (2006). Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. JOURNAL OF MEDICINAL CHEMISTRY, 49(3), 923-931.
Pochetti, G., Gavuzzo, E., Campestre, C., Agamennone, M., Tortorella, P., Consalvi, V., Gallina, C., Hiller, O., Tschesche, H., Tucker, P. A., et al. (2006). Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. JOURNAL OF MEDICINAL CHEMISTRY 49, 923-931.
Pochetti, G., et al., 2006. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. JOURNAL OF MEDICINAL CHEMISTRY, 49(3), p 923-931.
G. Pochetti, et al., “Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates”, JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, 2006, pp. 923-931.
Pochetti, G., Gavuzzo, E., Campestre, C., Agamennone, M., Tortorella, P., Consalvi, V., Gallina, C., Hiller, O., Tschesche, H., Tucker, P.A., Mazza, F.: Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. JOURNAL OF MEDICINAL CHEMISTRY. 49, 923-931 (2006).
Pochetti, G, Gavuzzo, E, Campestre, C, Agamennone, M, Tortorella, P, Consalvi, V, Gallina, C, Hiller, O, Tschesche, Harald, Tucker, PA, and Mazza, F. “Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates”. JOURNAL OF MEDICINAL CHEMISTRY 49.3 (2006): 923-931.
This data publication is cited in the following publications:
This publication cites the following data publications:

16 Citations in Europe PMC

Data provided by Europe PubMed Central.

Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors.
Tauro M, Loiodice F, Ceruso M, Supuran CT, Tortorella P., Bioorg. Med. Chem. Lett. 24(12), 2014
PMID: 24813742
Synthesis and antitumor activities of novel rhein α-aminophosphonates conjugates.
Yao GY, Ye MY, Huang RZ, Li YJ, Pan YM, Xu Q, Liao ZX, Wang HS., Bioorg. Med. Chem. Lett. 24(2), 2014
PMID: 24378217
Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P., Bioorg. Med. Chem. 21(21), 2013
PMID: 24071448
Synthesis, cytotoxicity, DNA binding and apoptosis of rhein-phosphonate derivatives as antitumor agents.
Ye MY, Yao GY, Wei JC, Pan YM, Liao ZX, Wang HS., Int J Mol Sci 14(5), 2013
PMID: 23629673
Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption.
Rubino MT, Agamennone M, Campestre C, Campiglia P, Cremasco V, Faccio R, Laghezza A, Loiodice F, Maggi D, Panza E, Rossello A, Tortorella P., ChemMedChem 6(7), 2011
PMID: 21714093
Identification of novel matrix metalloproteinase inhibitors by screening of phenol fragments library.
Rubino MT, Maggi D, Laghezza A, Loiodice F, Tortorella P., Arch. Pharm. (Weinheim) 344(9), 2011
PMID: 21695711
Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility.
Dorman G, Cseh S, Hajdu I, Barna L, Konya D, Kupai K, Kovacs L, Ferdinandy P., Drugs 70(8), 2010
PMID: 20481653
Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors.
Rubino MT, Agamennone M, Campestre C, Fracchiolla G, Laghezza A, Loiodice F, Nuti E, Rossello A, Tortorella P., ChemMedChem 4(3), 2009
PMID: 19204958
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
Ledour G, Moroy G, Rouffet M, Bourguet E, Guillaume D, Decarme M, Elmourabit H, Auge F, Alix AJ, Laronze JY, Bellon G, Hornebeck W, Sapi J., Bioorg. Med. Chem. 16(18), 2008
PMID: 18782669
Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains.
Gerhardt S, Hassall G, Hawtin P, McCall E, Flavell L, Minshull C, Hargreaves D, Ting A, Pauptit RA, Parker AE, Abbott WM., J. Mol. Biol. 373(4), 2007
PMID: 17897672
Novel hydroxamic acid-related phosphinates: inhibition of neutral aminopeptidase N (APN).
Drag M, Grzywa R, Oleksyszyn J., Bioorg. Med. Chem. Lett. 17(6), 2007
PMID: 17270439
alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.
Biasone A, Tortorella P, Campestre C, Agamennone M, Preziuso S, Chiappini M, Nuti E, Carelli P, Rossello A, Mazza F, Gallina C., Bioorg. Med. Chem. 15(2), 2007
PMID: 17088065
Recent advances in MMP inhibitor design.
Fisher JF, Mobashery S., Cancer Metastasis Rev. 25(1), 2006
PMID: 16680577

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 16451058
PubMed | Europe PMC

Search this title in

Google Scholar